Exelixis Inc. is unloading more than 53,000 square feet in South San Francisco to two up-and-coming companies.
Exelixis (NASDAQ: EXEL), which once had a workforce more than 600, said it will sublease 28,180 square feet at 170 Harbor Way to cancer drug maker Threshold Pharmaceuticals Inc. and 25,110 square feet in the same building to Nodality Inc., which is working on clinical tests that can predict cancer and autoimmune diseases.
No comments:
Post a Comment